A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses - American Association for Cancer Research (AACR)

Editorial Staff

Jul 16, 2026

A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses - American Association for Cancer Research (AACR)

After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some of the precancerous lesions shrank or stopped growing.

View Original Source Analyze with AI

Discussion (0)

No comments yet. Be the first to share your thoughts!

Join the Conversation

You need to be logged in to leave a comment.